Lakefront Biotherapeutics (LKFT) Liabilities from Discontinued Operations (2020 - 2023)
Lakefront Biotherapeutics (LKFT) reported Liabilities from Discontinued Operations of 9315533.65 for Q1 2023, down 12.38% quarter-over-quarter from 10631648.59 in Q4 2020.
Lakefront Biotherapeutics (LKFT) Liabilities from Discontinued Operations (2020 - 2023) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 9315533.65 in Q1 2023.
- Liabilities from Discontinued Operations for Q1 2023 came in at 9315533.65, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was 9315533.65 (changed N/A YoY), and the FY2020 annual result was 10631648.59, changed N/A from the prior year.
- Liabilities from Discontinued Operations eased to 9315533.65 in Q1 2023 per LKFT's latest filing, from 10631648.59 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 10631648.59 in Q4 2020 and troughed at 9315533.65 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 9.32 Mn |
| Mar 31, 2023 | 9.32 Mn |
| Dec 31, 2020 | 10.63 Mn |
| Dec 31, 2020 | 10.63 Mn |